Deficient metabolism of debrisoquine and sparteine
- 31 March 1980
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacology & Therapeutics
- Vol. 27 (4) , 547-549
- https://doi.org/10.1038/clpt.1980.77
Abstract
Genetic deficiencies of alicyclic hydroxylation of debrisoquine and of sparteine oxidation are independently discovered entities, each of clinical significance in its sphere. Evidence indicates that these 2 deficiencies have the same cause. Previous investigation of one of the affected subjects had revealed normal oxidative metabolism of amobarbital and antipyrine in terms of both metabolic rates and urinary metabolite patterns. The genetic defect in the metabolism of sparteine and debrisoquine is not a generalized deficiency of drug oxidation or of the cytochrome P450 system.This publication has 6 references indexed in Scilit:
- Antipyrine metabolism in man: simultaneous determination of norantipyrine and 4-hydroxyantipyrine in urine by gas chromatographyCanadian Journal of Physiology and Pharmacology, 1980
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- Distinctive patterns of amobarbital metabolitesClinical Pharmacology & Therapeutics, 1978
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Amobarbital—a probe of hepatic drug oxidation in manClinical Pharmacology & Therapeutics, 1976
- Gas-liquid chromatographic electron capture determination of some monosubstituted guanido-containing drugsAnalytical Chemistry, 1975